

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 September 2006 (28.09.2006)

PCT

(10) International Publication Number
WO 2006/100462 A1

(51) International Patent Classification:
C12Q 1/68 (2006.01)

(21) International Application Number:
PCT/GB2006/001014

(22) International Filing Date: 22 March 2006 (22.03.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0505763.3 22 March 2005 (22.03.2005) GB

(71) Applicant (for all designated States except US): **ENIGMA DIAGNOSTICS LTD** [GB/GB]; Building 224, Tetricus Sciences Park, DSTL, Porton Down, Salisbury, Wiltshire SP4 0JQ (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **SQUIRRELL, David, James** [GB/GB]; Enigma Diagnostics Ltd, Building 224, Tetricus Sciences Park, DSTL, Porton Down, Salisbury, Wiltshire SP4 0JQ (GB).

(74) Agents: **GREAVES, Carol, Pauline** et al.; Greaves Brewster LLP, Indigo House, Cheddar Business Park, Wedmore Road, Cheddar, Somerset BS27 3EB (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: POLYMORPHISM DETECTION METHOD

(57) Abstract: A method for detecting the presence or absence of a polymorphism at a particular position within a nucleic acid sequence in a sample, said method comprising i) annealing a pair of probes to said nucleic acid sequence, said probes being designed such that they anneal adjacent each other, and only completely anneal to one form of the sequence, in a reaction mixture which is substantially free of ATP; ii) ligating together any completely annealed pairs of probes in the presence of NAD and a nucleic acid ligase which uses NAD as a substrate/ iii) phosphorylating any AMP released by a ligation event to ATP, and iv) detecting ATP, in particular using a bioluminescent reaction, in the resultant reaction mixture. Kits for conducting this method are also described and claimed.



WO 2006/100462 A1

Polymorphism Detection Method

The present invention relates to a method for detecting specific nucleic acid sequences and in particular in
5 identifying sequences which contain polymorphisms or mutations, as well as to kits for carrying out the assay.

A wide variety of methods are becoming available to detect particular nucleic acid sequences, and, in particular to
10 determine the precise sequence of nucleic acids. Many of these are based upon nucleic acid amplification reactions such as the polymerase chain reaction (PCR) and the ligase chain reaction (LCR).

15 These methods are used in a wide variety of methods, to detect or diagnose for example diseases caused by pathogens such as bacteria and viruses. There are also particularly useful in genetic analysis or diagnosis, where the presence of a polymorphism, in particular a single nucleotide polymorphism
20 (SNP) can give rise to a disease state, or a predisposition towards a particular disease state.

With the completion of the sequencing of the human genome, and increasing knowledge of the relationship of particular
25 polymorphisms to particular diseases or predisposition to disease, the numbers of analyses which are being carried out for diagnostic purposes is increasing.

The ligase chain reaction is a particularly useful reaction for
30 the detection of polymorphisms. In this reaction, a pair of complementary probes, which, when the correct template is available, hybridise next to each other on the template, are added to the sample under test. They are subjected to conditions under which such hybridisation takes place, and then
35 ligated using a ligase enzyme, in the presence of a nucleotide

which is commonly adenosine tri-phosphate (ATP), but nicotinamide adenine dinucleotide (NAD) may also be used.

A 3-step ligation event occurs during this process, as
5 illustrated for example in an article by J.M.Pascal et al.,
Nature, (2004) 432, pp 473-478, resulting in the release of a
molecule of adenosine monophosphate (AMP) as a by-product of
each ligation event.

10 The ligated probes and the original template then serve as
additional templates for a further round of hybridisation and
ligation. This is effected by first heating the mixture so as
to denature the nucleic acid strands, for example, to
temperatures of from 80-90°C, suitably at about 85°C, and
15 thereafter, cooling to a temperature at which the probes anneal
and ligation occurs, for example from 40-60°C, typically at
about 50°C. As subsequent cycles are carried out, the
amplification but only if the correct template is present in
the sample.

20 By using four probes, one pair corresponding to each strand in
the original template molecule, which is double stranded,
exponential amplification can result. In this case, in a
preliminary step, the double stranded template DNA is
25 denatured.

Furthermore, in some cases, the probes are designed so that,
although they anneal close together, they are not directly
adjacent each other. In these cases, a polymerase, nucleotides
30 and other reagents necessary to allow the upstream probe to be
extended across the small gap (generally of 2-3 base pairs)
between the probes, is also included in the reaction mixture so
as to cause the upstream probe (which functions then as a
primer in an polymerase extension reaction) to extend across
35 the gap prior to ligation. Extension will only occur if the 3'

base of the upstream probe is matched to the corresponding base on the template, and so if it does not, as a result of a polymorphism or the like, then no subsequent ligation will occur.

5

Thereafter the product of the probe ligation can be detected by separating the products on the basis of size, for example on an electrophoretic gel, and staining the gel so as to detect them. Bands corresponding to a ligated probe will be larger than the individual probes, and so the presence of such a band will indicate that ligation has occurred and that the correct template was present in the sample.

This separation step and detection step is however slow and complex to perform. It can only be conducted in a laboratory environment and requires a substantial level of operator skill, and it requires a number of separate reaction stages.

In some instances, fluorescent dyes which associate with double stranded DNA and whose fluorescence changes when associated with double stranded DNA as compared to single stranded DNA may be added to the reaction mixture. If amplification has proceeded, then this will be detectable from the nature of the fluorescent signal from the dye. In this case however, it is necessary to measure the signal using a fluorimeter, which is a relatively complex apparatus. Fluorescent light of a particular wavelength must be supplied to the sample, and the emission signal, which is at a different wavelength measured.

According to the present invention there is provided a method for detecting the presence or absence of a polymorphism at a particular position within a nucleic acid sequence in a sample, said method comprising

i) annealing a pair of probes to said nucleic acid sequence, said probes being designed such that they anneal adjacent each

other, and only completely anneal to one form of the sequence, in a reaction mixture which is substantially free of ATP;

ii) ligating together any completely annealed pairs of probes in the presence of NAD and a nucleic acid ligase which uses NAD

5 as a substrate;

iii) phosphorylating any AMP released by a ligation event to ATP, and

iv) detecting ATP in the resultant reaction mixture.

10 Step (i) can be carried out in a method conventional in such reactions. Thus, the probes may bind directly adjacent to one another on the template strand, so that ligation occurs in step (ii) if the adjacent ends of the probes are perfectly matched to the template.

15

Alternatively the probes may bind so that there is a small gap therebetween, provided that there are no adenine bases in this gap region. In this case, the reaction mixture contains a polymerase, nucleotides other than adenine and any other

20 reagents necessary to extend the upstream primer to close the gap and allow ligation only if the 3' end of the probe matches the corresponding base on the template. If this base does not match, then probe extension across the gap will not occur and ligation in step (ii) will not result.

25

Using this method, a ligation reaction in (ii) will only occur if the sample contains a sequence to which both probes bind fully.

30 The presence of a nucleic acid sequence which gives rise to such a match can be determined by detecting ATP, derived from the AMP released during the ligation reaction, in step (iv).

If, as a result of a mutation or difference in the nucleic acid
35 sequence which forms the target of the assay, in particular at the position in which the probes bind adjacent to one another,

an end of one of the probes does not bind to the target, then the ligation event will not take place in step (ii). As a result no AMP is generated, and so phosphorylation in step (iii) will not give rise to any ATP. The absence of ATP in the
5 reaction mixture in step (iv) will indicate that the sample does not contain the target nucleic acid, and therefore the presence of a different form may be likely.

Nucleic acid ligases which are able to utilise NAD as well as
10 or instead of ATP as a substrate are known. A particular example of such a ligase is *E.coli* ligase.

The AMP by-product of the ligation may be phosphorylated during step (iii) to ATP enzymatically either directly or by way of
15 the production of adenosine diphosphate (ADP).

The one or more enzymes necessary to convert AMP produced to ATP (step (iii) above), may for example be selected from phosphoenolpyruvate synthase which produces ATP directly from
20 AMP in the presence of phosphate and phosphoenolpyruvate, which are also added as a reagent to the reaction mixture. Alternatively, a combination of a nucleoside triphosphate-adenylate kinase and NTP will yield adenosine diphosphate (ADP), which may then be converted to ATP by inclusion or
25 addition of an enzyme such as adenylyate kinase.

Yet further examples of suitable enzymes include pyruvate phosphate dikinase such as that described by Eisaki et al, Biochim. et Biophys Acta 1431 (1999) 363-373.

30 By using NAD instead of ATP, which is conventionally utilised in LCR, the possibility arises that a signalling system based upon ATP detection may be used.

35 Various systems of this type are known. However they can generally be carried out rapidly, and give for example clear

visible signals *in situ*. As a result, the ligation reaction can be determined in a homogenous manner, without the need for analysis of the sizes of the ligation products.

- 5 In particular, the ATP is detected using a bioluminescent system. Examples of the application of such detection systems are described for example in WO 96/02665.

10 Particularly suitable bioluminescent reagents, which react to the presence of ATP, include luciferin and luciferase, accompanied if necessary by a source of magnesium ions such as magnesium acetate. In the presence of ATP, these reagents produce a luminescent signal, which can be readily monitored for example using conventional luminometer devices. These are
15 generally much simpler to operate and use than say a fluorimeter.

In generating a signal, these reagents regenerate an AMP molecule, which in the presence of the enzymes and/or reagents
20 of (iii), will be reconverted back to ATP. Thus the signal builds up exponentially and so will be readily and rapidly detected. An example of such a system is described by Sakakibara et al., Analytical Biochemistry, 268, 94-101 (1999). This exponential rise in signal may mean that detection can be
25 carried out directly, in circumstances where amplification reactions may previously have been required.

Bioluminescent signalling systems are more sensitive than fluorescent systems.

30 Furthermore, detection of such a reaction can be carried out simply and easily, using simple a light detector such as a camera. The use of complex equipment, such as fluorimeters and the like, necessary to detect signals in the widely used
35 fluorescent signalling systems is thus avoided.

Suitably, the method described above forms a part of a ligase chain reaction (LCR). This amplification reaction may be conducted in the usual way, for example by cycling the reaction mixture through denaturation, and annealing/ligation

5 temperatures. Thus, effectively steps (i) and (ii) above are repeated until the desired level of amplification has been achieved.

Suitably the reaction is conducted with two pairs of probes,
10 one corresponding to each strand of a double stranded template nucleic acid sequence, so that amplification can proceed exponentially. In this case, the double stranded template nucleic acid is denatured prior to step (i).

15 Where this is the case, at least step (iv) and suitably steps (iii) and (iv) above may be carried out at the end of the reaction. This provides a good end-point detection method.

If desired however, the phosphorylating and bioluminescent
20 reagents are present or added throughout the amplification reaction so that the progress of the reaction can be monitored. Generally speaking, the thermostability of reagents such as luciferase is not sufficient to allow it to be present throughout an amplification reaction that involves significant
25 thermal cycling, and thus, it is suitably added at the end of each cycle, and measurements taken before the next cycle commences. However, the selection of thermostable luciferase enzymes such as those described for example in EP-A-524448, WO95/25798, WO 99/14336, WO 00/24878, WO01/31028 and
30 WO2003/0068801 may facilitate some monitoring reaction of step (iv) to be carried out continuously through the LCR.

In particular, this may be further facilitated if the reaction conditions or reagents used in the LCR are such as to reduce or
35 minimise the extent of the thermal cycling in terms of the

range of temperatures which are required in order to achieve the desired result.

- For example, it is possible to lower the denaturation temperature required by addition of reagents such as Betain (N,N,N-trimethylglycine) or increasing the volume of the solvents such as dimethylsulphoxide (DMSO) or dimethylformamide (DMF).
- 10 Addition of enzymes which destabilise duplexes such as topoisomerase or DNA gyrase may also be effective in reducing the denaturation temperatures to those which may be tolerated by luciferase enzymes. The amounts of these enzymes should be sufficient to ensure that there is an equilibrium reaction
- 15 going on so that annealing and ligation is possible, if the temperature is reduced below that at which the destabilising enzymes is fully active.

- In yet a further alternative, denaturation may be effected in a substantially isothermal manner, for example by applying electrochemical potentials to the reaction mixture in order to bring about a denaturation step.

- Additionally, a luciferin recycling protein, which regenerates luciferin from oxyluciferin, such as those described in US Patent No. 5,814,504 and WO 03/042693 may be added to the reaction mixture, to avoid the need to continuously add luciferin to the reaction mixture.

- 30 Such information may be used then in the quantification of the target nucleic acid sequence in the sample, using algorithms etc. which are known in the art.

- The reaction as described above could be carried out in a variety of conventional equipment. These include for example a Pyrosequencer (available from Pyrosequencing AB, Sweden), which

is already provided with appropriate signal detection means. Alternatively, the reaction may be carried out using block heating devices as described for example in EP-A-0810030 and supplied by The Perkin-Elmer Corporation, rapid hot air thermal cyclers such as the RapidCycler™ and LightCycler™ from Idaho Technologys Inc. or other types of thermal cycler such as those described in WO98/24548.

In order to ensure that no, or at least a very low level of ATP is present in the sample before the assay, it may be preferable to carry out a pre-treatment step in which ATP is removed. This may be done for example if the sample containing the nucleic acid sequence is treated with apyrase to remove ATP, although since this may lead to some AMP production, it may be preferable to apply a deaminase, which destroys the adenosine residue. However, the bead wash steps should ensure effective separation of nucleic acids from the adenylates due to the increased binding of DNA thereto, and so the process can be carried out in the absence of any such step.

The method can be used in any applications in which LCR is currently feasible, both in detection of sequences such as microorganisms, virus or other pathogens, or in the diagnosis of disease. Suitably therefore the sample is a genetic sample.

In a further aspect the invention provides a kit for carrying out a method as described above, said kit comprising a nucleic acid ligase which uses NAD as a substrate, a phosphorylating agent, and one or more reagents able to produce a bioluminescent signal.

Suitable phosphorylating agents include enzymes such as those described above including a combination of phosphoenolpyruvate synthase, phosphate and phosphoenolpyruvate; a combination of a nucleoside triphosphate-adenylate kinase, NTP and adenylate kinase; or pyruvate phosphate dikinase.

Suitable reagents able to produce a bioluminescent reaction systems comprise luciferase and/or luciferin. Optionally, the kit may also comprise magnesium salts required to activate the luciferase/luciferin system, but which may also be used in the LCR.

The kit may further comprise a pair of probes suitable for annealing to a target nucleic acid, and preferably two pairs of probes, each pair being capable of annealing to corresponding regions on opposite strands of a target double stranded nucleic acid.

The kit may further comprise other reagents suitable for conducting LCR, for example NAD, a buffer (such as 250mM EPPS [N-2-hydroxyethyl)piperazine-N-(3-propanesulphonic acid), or potassium salts.

Additionally, it may also include apyrase enzyme or more suitably a deaminase enzyme to carry out the pre-treatment step outlined above.

The invention will now be particularly described by way of example with reference to the accompanying diagrammatic drawing, which illustrates schematically, a method according to the invention.

In this reaction scheme, steps 1 to 3 represent a conventional cycle in an LCR reaction, with the exception only that NAD is used as the substrate for the ligase enzyme (NH₂-LysLig). In the first stage, the NAD becomes bound to the enzyme and disassociated to AMP (which is not available for phosphorylation at this stage). Pyrophosphate (PPi) is released by this process. In the presence of template DNA (1) having an upstream probe (2) and a downstream probe (3) hybridised thereto, the enzyme transfers its AMP to the 5' end

of the downstream probe (3), which then ligates to the free hydroxy group at the 3' end of the upstream probe (2), forming a ligate (4) and releasing free AMP (Step 3).

- 5 The addition or presence of phosphorylating enzymes at this stage will result in conversion of the free AMP to ATP, which can then be detected in a conventional luciferase/luciferin bioluminescent reaction, illustrated at Step 4.
- 10 The system of the reaction therefore provides a reliable and easy to operate assay, in particular for the detection of polymorphisms, such as SNPs, in particular as set out in Example 1.
- 15 Example 1
A. Sample preparation
This can be carried out on an instrument such as the Thermo Labsystem KingFisher machine.
- 20 A blood sample (200µl) is added to 300µl of 3.8M guanidium hydrochloride. This is then mixed for 1 minute at room temperature to lyse cellular material and release DNA. Promega MagneSil KF paramagnetic particles (20µl) are added (these may be stored in a well containing the first wash solution (see
- 25 below) and transferred in from that well) and mixed for 2 minutes. Extracted DNA binds to the silica particles. The particles with bound DNA are then magnetically transferred into the first wash well which contains a 50% mixture of ethanol and TE buffer at pH 7.4 (TE buffer is 10mM Tris.HCl with 1mM EDTA).
- 30 The beads are released and mixed with the first wash solution for 1 minute. This is repeated with two more identical wash solutions. After the 3rd wash the beads are transferred into a TE buffer at pH8.3 at a temperature of >50°C with mixing for 12 minutes when the DNA is eluted from the silica matrix. The
- 35 beads are then removed and disposed of in one of the wash wells and the prepared DNA used for the next step.

Ligase Chain Reaction (LCR)

This can be performed in a block thermal cycler such as the Perkin Elmer 9600.

5

The DNA is mixed with an equal volume of LCR Assay Mix to give a final reaction volume of 50µl with the solution containing 20mM Tris.HCl, pH 7.6, buffer containing 100mM KCl, 10mM MgCl₂, 1mM EDTA, 10mM dithiothreitol, 10mM NAD⁺, 4µg/mL salmon sperm DNA, 15 units *T.aquaticus* ligase with the two diagnostic oligonucleotides at a concentration of 5µM each. The reaction is carried out with a thermal profile of 94°C for 1 min and 65°C for 4 minutes, repeated for 40 cycles. Bioluminescent detection of AMP formed from the NAD is then used to indicate whether or not LCR occurred. The diagnostic oligonucleotides are designed to have a melting temperature about 2°C above 65°C.

10

15

Bioluminescent detection

20

The assays can be performed, at room temperature, in 100µl volumes in 96 well microtitre plates using a Labsystems Luminoskan Ascent plate luminometer from Thermo Labsystems.

25

30

The added bioluminescent assay mix contains 20units/ml adenylate kinase, 5mM acetyl phosphate, 2units/ml acetate kinase, 300ng/ml firefly luciferase and 1mM D-luciferin in 90mM Tris-HCl, 10mM MgCl₂, 1mM EDTA and 10mM dithiothreitol, to give a final pH of 7.9. Light emission is high where the diagnostic oligonucleotides end-match the complementary bases in the DNA target eg where positive detection of a single nucleotide polymorphism (SNP) is indicated.

Claims

1. A method for detecting the presence or absence of a polymorphism at a particular position within a target nucleic acid sequence in a sample, said method comprising
 - i) annealing a pair of probes to said nucleic acid sequence, said probes being designed such that they anneal adjacent each other, and only completely anneal to one form of the sequence, in a reaction mixture which is substantially free of ATP;
 - 10 ii) ligating together any completely annealed pairs of probes in the presence of NAD and a nucleic acid ligase which uses NAD as a substrate;
 - iii) phosphorylating any AMP released by a ligation event to ATP, and
 - 15 iv) detecting ATP in the resultant reaction mixture.
2. A method according to claim 1 wherein ATP is detected using a bioluminescent system.
- 20 3. A method according to claim 2 wherein the bioluminescent system is the luciferase/luciferin system.
4. A method according to any one of the preceding claims wherein as a pre-treatment step, the sample containing the nucleic acid sequence is treated to remove ATP therefrom.
- 25 5. A method according to claim 4 wherein the sample is a genetic sample.
- 30 6. A method according to any one of the preceding claims wherein the nucleic acid ligase is a thermostable ligase, and the method forms part of a ligase chain reaction.
7. A method according to any one of the preceding claims wherein two pairs of probes are used, one pair corresponding to each strand of a double stranded target nucleic acid.
- 35

8. A method according to any one of the preceding claims wherein pairs of probes anneal directly adjacent each other on the target nucleic acid strand.

5

9. A method according to any one of claims 1 to 7 wherein pairs of probes bind so that there is a small gap, which does not contain any adenine bases therebetween, and the reaction mixture further contains a polymerase and nucleotides suitable for extending the upstream probe across said gap, provided the 3' end of the upstream probe matches the corresponding base on the target nucleic acid.

10

10. A kit for carrying out a method according to any one of the preceding claims, said kit comprising a nucleic acid ligase which uses NAD as a substrate, a phosphorylating agent, and one or more reagents able to produce a bioluminescent signal.

15

11. A kit according to claim 10 wherein the phosphorylating agent is a combination of phosphoenolpyruvate synthase, phosphate and phosphoenolpyruvate; a combination of a nucleoside triphosphate-adenylate kinase, NTP and adenylate kinase; or pyruvate phosphate dikinase.

20

12. A kit according to claim 10 or claim 11 wherein the one or more reagents able to produce a bioluminescent signal comprise luciferase and/or luciferin.

25

13. A kit according to any one of claims 10 to 12 which further comprises a pair of probes suitable for annealing to a target nucleic acid.

30

14. A kit according to claim 13 which comprises two pairs of probes, each pair being capable of annealing to corresponding regions on opposite strands of a target double stranded nucleic acid.

5


15. A kit according to any one of claims 10 to 14 which further comprises magnesium salts.

16. A kit according to any one of claims 10 to 15 which
10 further comprises one or more of NAD, a buffer, or potassium salts.


17. A kit according to any one of claims 10 to 16 which further includes an deaminase enzyme.

Figure 1


Step 1






Step 2



Step 3



Step 4



INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2006/001014

A. CLASSIFICATION OF SUBJECT MATTER

INV. C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2005/003386 A (BIOTAGE AB; TOOKE, NIGEL; EKSTROEM, BJOERN) 13 January 2005 (2005-01-13)	1-5, 7, 8, 10-17
Y	page 4, line 16 - page 5, line 2; page 27, lines 13-16; page 28, lines 10-24; page 29, lines 4-20; page 30, line 1 - page 31, line 9; examples 1-2; claims ----- -/--	6

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

5 July 2006

Date of mailing of the international search report

17/07/2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hennard, C

INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2006/001014

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	TANNOUS B A ET AL: "Combined flash- and glow-type chemiluminescent reactions for high-throughput genotyping of biallelic polymorphisms" ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 320, no. 2, 15 September 2003 (2003-09-15), pages 266-272, XP004447154 ISSN: 0003-2697 page 268, right-hand column, middle paragraph; page 270, figure 4 -----	6
A	US 2003/124544 A1 (KAMBARA HIDEKI ET AL) 3 July 2003 (2003-07-03) examples 3, 5, 8 -----	1-17
A	US 2004/197793 A1 (HASSIBI ARJANG [US] ET AL) 7 October 2004 (2004-10-07) examples 5, 6; claims 1-7 -----	1-17

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2006/001014

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2005003386 A	13-01-2005	EP 1639132 A2	29-03-2006
US 2003124544 A1	03-07-2003	JP 2003135097 A	13-05-2003
US 2004197793 A1	07-10-2004	NONE	